Jay K. Trautman

Cequent Pharmaceuticals, Inc. developed therapeutics and pharmaceuticals. The company was founded in 2006 and was headquartered in Cambridge, MA.

SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA.

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.

Direct Vet Marketing, Inc. provides cloud-based prescription management, pharmacy services, marketing solutions and practice analytics for equine and companion animal veterinary practitioners. It offers online ordering and home delivery of prescription drugs, compounded medications, and therapeutic diets. The company was founded by David Evans Shaw and Benjamin J. Shaw in 2010 and is headquartered in Portland, Maine.

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Novartis Option Fund invests in early stage biotech start-ups with innovative technology platform enabling the development of novel programs and technologies. The individual investment is coupled with an option to a specific therapeutic program. The fund targets two or more investments per year which would be financed in a syndicate with other VCs and intends to make follow-on investments.

Thermalin, Inc. engages in the development of insulin products for patients with diabetes. It offers stabilized, ultra-rapid, and highly concentrated; no refrigeration basal and mix; glucose-responsive smart basal; and StampPump insulins. The company was founded by Michael A. Weiss, Bruce H. Frank, and Richard Berenson in 2010 and is headquartered in Cleveland, OH.

Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA.

BioInnovation Management LLC (Bioinnovation Management) is a venture capital firm founded in 2009 by Peter D Parker and Susie T Harborth. The firm is headquartered in Cambridge, Massachusetts.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Prolynx LLC engages in the development of proprietary drug delivery system for half-life extension of proteins, peptides, and small molecules. Its pipeline includes PLX038, PEG-PARP, IL-15, IL-2, PTH 1-34, GLP-1RA, and QMo IVT. The company was founded by Daniel V. Santi and Gary W. Ashley in 2010 and is headquartered in San Francisco, CA.

Mindimmune Therapeutics, Inc. develops drugs that target the immune system to treat diseases of the central nervous system. It focuses on the treatment of Alzheimer's, Huntington's disease, pain, and psychiatric disorders. The company was founded by Stevin Zorn, Frank S. Menniti, Robert B. Nelson, and Brian M. Campbell on July 12, 2016 and is headquartered in Kingston, RI.

LabCentral, Inc. provides grant making services for bio-tech companies. The firm?s services include maintenance of permits for all lab operations, mandatory EHS training and compliance for all lab users, maintenance of equipment and technical support, CRO support available on-site (FTE basis), cleaning and waste removal. The company was founded by Timothy D. Rowe, Johannes Fruehauf, Peter D. Parker in September 2012 and is headquartered in Cambridge, MA.

Eikonizo Therapeutics, Inc. provides healthcare services. The company was founded in 2017 and is headquartered in Beverly, MA.

Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA.

Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA.

Vedere Bio, Inc. develops cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss. The company was founded in June 2019 and is headquartered in Cambridge, MA.

Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients.

Jupiter Bioventures LLC is a biotech company studio that aims to create innovative companies and develop groundbreaking medicines. The company is based in Wilmington, DE. The CEOs of the company are Nathaniel E. David, Norman E. Sharpless.

Arclight Therapeutics LLC is an American bio-pharmaceutical company founded by Steven Tregay. The company operates in the field of developing and producing pharmaceutical products.

Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation.

Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.